{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:44Z","timestamp":1789656044901,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":220,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.gastha.2024.08.008","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:24:48Z","timestamp":1723681488000},"page":"1120-1128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-5199","authenticated-orcid":false,"given":"Miwa","family":"Kawanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1900-4389","authenticated-orcid":false,"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Kubotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hyogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Kawanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2024.08.008_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.008_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","article-title":"The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040","volume":"15","author":"Ito","year":"2021","journal-title":"Hepatol Int"},{"issue":"7","key":"10.1016\/j.gastha.2024.08.008_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.gastha.2024.08.008_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101274","article-title":"NAFLD-A rising metabolic disease","volume":"50","author":"Zeigerer","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.gastha.2024.08.008_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.gastha.2024.08.008_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.08.008_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cgh.2022.01.002","article-title":"Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study","volume":"21","author":"Fujii","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/hepr.13382","article-title":"Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"49","author":"Honda","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastha.2024.08.008_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/life11020143","article-title":"FIB-4 first in the diagnostic algorithm of metabolic-dysfunction-associated fatty liver disease in the era of the global metabodemic","volume":"11","author":"Sumida","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.gastha.2024.08.008_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.5604\/16652681.1171767","article-title":"Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease","volume":"14","author":"Kawanaka","year":"2015","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00535-022-01932-1","article-title":"SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum","volume":"58","author":"Kamada","year":"2023","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.gastha.2024.08.008_bib13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.08.008_bib15","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.28002","article-title":"A\u00a0novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers","volume":"62","author":"Kamada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.008_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gastha.2024.08.008_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0016-5085(03)00907-7","article-title":"Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis","volume":"125","author":"Feldstein","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.08.008_bib18","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.008_bib19","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.3350\/cmh.2022.0426","article-title":"Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future","volume":"29","author":"Yip","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib20","first-page":"341","article-title":"Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.gastha.2024.08.008_bib21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hepr.12197","article-title":"Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: a meta-analysis","volume":"44","author":"Chen","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastha.2024.08.008_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.gastha.2024.08.008_bib23","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep4.1971","article-title":"A\u00a0new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis","volume":"6","author":"Eguchi","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastha.2024.08.008_bib24","article-title":"Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2024.08.008_bib25","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.008_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.08.008_bib27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.008_bib28","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000066","article-title":"Multicenter validation study of a diagnostic algorithm to detect NASH and fibrosis in NAFLD patients with low NAFLD fibrosis score or liver stiffness","volume":"10","author":"Liebig","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.gastha.2024.08.008_bib29","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.008_bib30","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib32","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.008_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.008_bib35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"Kwok","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2024.08.008_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib37","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jhep.2011.12.025","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers","volume":"56","author":"Shen","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/MEG.0000000000002176","article-title":"Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"33","author":"Tada","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12876-023-02786-4","article-title":"Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis","volume":"23","author":"Kawanaka","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastha.2024.08.008_bib40","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.08.008_bib41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.dld.2007.10.019","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD)","volume":"40","author":"Yoneda","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastha.2024.08.008_bib42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/hepr.13508","article-title":"Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: comparison between M and XL probes","volume":"50","author":"Oeda","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastha.2024.08.008_bib44","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jhep.2022.07.020","article-title":"Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD","volume":"77","author":"Kim","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.008_bib45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/hepr.13884","article-title":"Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease","volume":"53","author":"Fujii","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastha.2024.08.008_bib46","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00280-007-0437-4","article-title":"Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma","volume":"60","author":"Cummings","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.gastha.2024.08.008_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2022.111806","article-title":"Impact of duodenal-jejunal bypass liner (DJBL) on NAFLD in patients with obesity and type 2 diabetes mellitus","volume":"103-104","author":"Roehlen","year":"2022","journal-title":"Nutrition"},{"key":"10.1016\/j.gastha.2024.08.008_bib48","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/antiox12040833","article-title":"Mediterranean diet improves plasma biomarkers related to oxidative stress and inflammatory process in patients with non-alcoholic fatty liver disease","volume":"12","author":"Quetglas-Llabres","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.gastha.2024.08.008_bib49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A\u00a0phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N\u00a0Engl J Med"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:37:18Z","timestamp":1733013438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572324001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2772572324001225"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2024.08.008","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}